Announced
Completed
Halozyme Therapeutics completed the acquisition of Surf Bio for $400m.
Synopsis
Halozyme Therapeutics, a biopharmaceutical company, completed the acquisition of Surf Bio, a preclinical biopharmaceutical company, for $400m.
Principals
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
Claim DealAll rights reserved. Copyright © 2026 Datasite